Cannabisbezogene Störungen

Lernziele

Kenntnisse über

die körperlichen und psychischen Folgestörungen der Cannabisabhängigkeit, die körperlichen und psychischen Begleiterkrankungen der Cannabisabhängigkeit.

Literatur

• 1 Bonnet U, Scherbaum N. Evidenzbasierte Behandlung der Cannabisabhängigkeit. Backmund M Suchttherapie Landsberg; Ecomed 2007 Kap. IX 3. 1-28
• 2 Dannon P N, Lowengrup K, Amiaz R. et al . Comorbid cannabis use and panic disorder: short term and long term follow-up.  Hum Psychopharmacology. 2004;  19 97-101
• 3 Johns A. Psychiatric effects of cannabis.  British J Psychiatr. 2001;  178 116-122
• 4 Degenhardt L, Hall W, Lynskey M. Alcohol, cannabis and tobacco use among Australians: a comparison of their associations with other drug use and use disorders, affective and anxiety disorders, and psychosis.  Addiction. 2001;  96 1603-1614
• 5 Bonnet U, Harries-Hedder K, Leweke F M. et al .AWMF-Leitlinie: Cannabis-bezogene Störungen. LG Schmidt, M Gastpar, P Falkai, et al Evidenzbasierte Suchtmedizin Köln; Deutscher Ärzte-Verlag 2006: 143-170
• 6 Budney A J, Hughes J R, Moore B A. et al . Review of the validity and significance of cannabis withdrawal syndrome.  Am J Psychiatry. 2004;  161 1967-1977
• 7 Budney A J, Vandrey R G, Hughes J R. et al . Comparison of cannabis and tobacco withdrawal : severity and contribution to relapse.  J Substance Abuse treat. 2008;  35 362-368
• 8 Cornelius J R, Chung T, Martin C. et al . Cannabis withdrawal is common among treatment-seeking adolescents with cannabis dependence and major depression, and is associated with rapid relapse to dependence.  Addict Behav. 2008;  33 1500-1505
• 9 Benyamina A, Lecacheux M, Blecha L. et al . Pharmacotherapy and psychotherapy in cannabis withdrawal and dependence.  Expert Rev Neurother. 2008;  8 479-491
• 10 Nunez L A, Gurpegui M. Cannabis-induced psychosis: a cross-sectional comparison with acute schizophrenia.  Acta Psychiatr Scand. 2002;  105 173-178
• 11 Leweke F M, Koethe D. Cannabis and psychiatric disorders: it is not only addiction.  Addict Biol. 2008;  13 264-275
• 12 Gaillard M C, Borruat F X. Persisting visual hallucinations and illusions in previosly drug-addicted patients.  Klin Montsbl Augenheilk. 2003;  220 176-178
• 13 Täschner K L. Cannabis. Biologie, Konsum und Wirkung. Köln; Deutscher Ärzte-Verlag 2005
• 14 Pope H G, Gruber A J, Hudson J I. et al . Neuropsychological performance in long-term cannabis users.  Arch Gen Psychiatry. 2001;  56 909-915
• 15 Grant Jr I, Gonzales R, Carey C L. et al . Non-acute (residual) neurocognitive effects of cannabis use: a meta-analytic study.  Journal of the International Neuropsychological Society. 2003;  9 679-689
• 16 Solowji N, Roffman R A, Barbor T. et al . Cognitive functioning of long-term heavy cannabis users seeking treatment.  JAMA. 2002;  287 1123-1131
• 17 Fried P A. Current and former marijuana use: preliminary findings of a longitudinal study of effects on IQ in young adults.  Canadian Medical Association Journal. 2002;  166 887-891
• 18 Bolla K I. Dose related neurocognitive effects of marijuana use.  Neurology. 2002;  59 1337-1343
• 19 Pope jr H G, Gruber A J, Hudson J I. et al . Early-onset cannabis use and cognitive deficits: what is the nature of the association?.  Drug Alcohol Depend. 2003;  69 303-310
• 20 Petersen K U, Thomasius R. Auswirkungen von Cannabiskonsum und -missbrauch. Eine Expertise zu gesundheitlichen und psychosozialen Folgen. Ein systematisches Review der international publizierten Studien von 1996 – 2006. Lengerich; Pabst-Verlag 2007
• 21 Kendler K S, Prescott C A. Cannabis use, abuse, and dependence in a population-based sample of female twins.  Am J Psychiatry. 1998;  155 1016-1022
• 22 Kandel D, Chen K. Types of marihuana users by longitudinal course.  J Stud Alcohol. 2000;  61 367-378
• 23 Henquet C, Krabbendam L, Graaf de R. et al . Cannabis use and expression of mania in the general population.  J Affect Disord. 2006;  95 103-10
• 24 Harder V S, Morral A R, Arkes J. Marijuana use and depression among adults: testing for causal associations.  Addiction. 2006;  101 1463-1472
• 25 Watzke A B, Schmidt C O, Zimmermann J. et al . Personality disorders in a clinical sample of cannabis dependent young adults.  Fortschr Neurol Psychiatr. 2008;  76 600-605
• 26 Tournier M, Sorbara F, Gindre C. et al . Cannabis use and anxiety in daily life: a naturalistic investigation in a non-clinical population.  Psychiatry Res. 2003;  118 1-8
• 27 Green A I, Burgess E S, Dawson R. et al . Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone.  Schizophr res. 2003;  60 81-85
• 28 Stuyt E B, Sajbel T A, Allen M H. Differing effects of antipsychotic medications on substance abuse treatment patients with co-occurring psychotic and substance abuse disorders.  Am J Addict. 2006;  15 166-173
• 29 Potvin S, Stip E, Lipp O. et al . Quetiapine in patients with comorbid schizophrenia-spectrum and substance disorders: an open-label trial.  Curr Med Res Opin. 2006;  22 1277-1285
• 30 Van Nimwegen L J, Haan de L, Beberen N J. et al . Effect of olanzapine and risperidone on subjective well-being and craving for cannabis in patients with schizophrenia or related disorders: a double-blind randomized controlled trial.  Can J Psychiatry. 2008;  53 400-405
• 31 Edwards van J, Elkins K, Hinton M. et al . Randomized controlled trial of a cannabis-focused intervention for people with first-episode psychosis.  Acta Psychiatr Scand. 2006;  114 109-117
• 32 Bellack A s, Bennett M E, Gearon J S. et al . A randomized clinical trial of a behavioral treatment for drug abuse in people with severe and persistent mental illness.  Arch Gen Psychiatry. 2006;  63 426-432
• 33 Sigmon S C, Higgins S T. Voucher-based contingent reinforcement of marijuana abstinence among individuals with serious mental illness.  J Subst Abuse Treat. 2006;  30 291-295
• 34 Fergusson D M, Horwood J. Does cannabis use encourage other forms of illicit drug use?.  Addiction. 2000;  95 505-520
• 35 Simon R, Sonntag D, Bühringer G. et al .Cannabisbezogene Störungen: Umfang, Behandlungsbedarf und Behandlungsangebot in Deutschland. München; IFT 2004
• 36 Jones R T. Cardiovascular system effects of marijuana.  J Clin Pharmacol. 2002;  42 (11 Suppl) 58S-63S
• 37 Peyrot I, Garsaud A M, Saint-Cyr I. et al . Cannabis arteriitis: a new case report and a review of literature.  J Eur Acad Dermatol Venereol. 2007;  21 388-391
• 38 Wargo K A, Geveden B, McConnell V J. Cannabinoid-induced pancreatitis: a case series.  JOP. 2007 (online);  8 579-583
• 39 Boratyrewicz M, Urasinska E, Rozanski J. et al . Membranous glomerulonephritis may be associated with heavy marijuana abuse.  Transplant Proc. 2007;  39 3054-3056
• 40 Schwartz R H. Marijuana: a decade and a half later, still a crude drug with underappreciated toxicity.  Pediatrics. 2002;  109 284-289
• 41 Allen J H, Moore G M, Twartz J C. Cannabinoid hyperemesis: cyclical hyperemesis in association with chronic cannabis abuse.  Gut. 2004;  53 1566-1570
• 42 Hezode de C, Zafrani E S, Roudot-Thoraval F. et al . Daily cannabis use: a novel risk factor of steatosis severity in patients with chronic hepatitis C?.  Gastroenterology. 2008;  134 432-439
• 43 Weintrieb R M, Lucey M R. Treatment of addictive behaviors in liver transplant patients.  Liver Transplantation. 2007;  13 (Suppl 2) S79-S82
• 44 Taylor D R, Fergusson D M, Milne B J. et al . A longitudinal study of the effects of tobacco and cannabis exposure on lung function in young adults.  Addiction. 2002;  97 1055-1061
• 45 Fried P A, Smith A M. A literature review of the consequences of prenatal marihuana exposure: an emerging theme of a deficiency in aspects of executive function.  Neurotoxicol Teratol. 2001;  23 1-11
• 46 Busse F P, Fiedler G M, Leichtle A. et al . Bleiintoxikationen durch gestrecktes Marihuana in Leipzig.  Deutsches Ärzteblatt. 2008;  105  757-62
• 47 Brandenburg D, Wernick R. Intraveneous marijuana syndrome.  West J Med. 1986;  145 94-96
• 48 Robson P. Human studies of cannabinoids and medical cannabis.  Handb Exp Pharmacol. 2005;  168 719-756